Angela B S Santos1, Gabriela Querejeta Roca1, Brian Claggett1, Nancy K Sweitzer1, Sanjiv J Shah1, Inder S Anand1, James C Fang1, Michael R Zile1, Bertram Pitt1, Scott D Solomon1, Amil M Shah2. 1. From the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (A.B.S.S., G.Q.R., B.C., S.D.S., A.M.S.); Cardiology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal of Rio Grande do Sul, Porto Alegre, Brazil (A.B.S.S.); Division of Cardiovascular Medicine, Sarver Heart Center, University of Arizona College of Medicine, Tucson (N.K.S.); Cardiology Division, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Cardiovascular Division, VA Medical Center, Minneapolis, MN (I.S.A.); Cardiology Division, University of Utah School of Medicine, Salt Lake City (J.F.); RHJ Department of Veterans Affairs Medical Center, Medical University of South Carolina, Charleston (M.R.Z.); and Cardiology Division, University of Michigan School of Medicine, Ann Arbor (B.P.). 2. From the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (A.B.S.S., G.Q.R., B.C., S.D.S., A.M.S.); Cardiology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal of Rio Grande do Sul, Porto Alegre, Brazil (A.B.S.S.); Division of Cardiovascular Medicine, Sarver Heart Center, University of Arizona College of Medicine, Tucson (N.K.S.); Cardiology Division, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Cardiovascular Division, VA Medical Center, Minneapolis, MN (I.S.A.); Cardiology Division, University of Utah School of Medicine, Salt Lake City (J.F.); RHJ Department of Veterans Affairs Medical Center, Medical University of South Carolina, Charleston (M.R.Z.); and Cardiology Division, University of Michigan School of Medicine, Ann Arbor (B.P.). ashah11@partners.org.
Abstract
BACKGROUND: Left atrial (LA) size is an established marker of risk for adverse outcomes in heart failure with preserved ejection fraction (HFpEF). However, the independent prognostic importance of LA function in HFpEF is not known. METHODS AND RESULTS: We assessed LA function measured by speckle-tracking echocardiography in 357 patients with HFpEF enrolled in the Treatment Of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial who were in sinus rhythm at the time of echocardiography. Lower peak LA strain, indicating LA dysfunction, was associated with older age, higher prevalence of atrial fibrillation and left ventricular (LV) hypertrophy, worse LV and right ventricular systolic function, and worse LV diastolic function. At a mean follow-up of 31 months (interquartile range, 18-43months), 91 patients (25.5%) experienced the primary composite end point of cardiovascular death, HF hospitalization, and aborted sudden death. Lower peak LA strain was associated with a higher risk of the composite end point (hazard ratio, 0.96 per unit of reduction in strain; 95% confidence interval, 0.94-0.99; P=0.009) and of HF hospitalization alone (hazard ratio, 0.95 per unit of reduction in strain; 95% confidence interval, 0.92-0.98; P=0.003). The association of LA strain with incident HF hospitalization remained significant after adjustment for clinical confounders, but not after further adjustment for LV global longitudinal strain and the E/E' ratio, parameters of LV systolic and diastolic function, respectively. CONCLUSIONS: LA dysfunction in HFpEF is associated with a higher risk of HF hospitalization independent of potential clinical confounders, but not independent of LV strain and filling pressure. Impairment in LV systolic and diastolic function largely explains the association between impaired LA function and higher risk of HF hospitalization in HFpEF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.
RCT Entities:
BACKGROUND: Left atrial (LA) size is an established marker of risk for adverse outcomes in heart failure with preserved ejection fraction (HFpEF). However, the independent prognostic importance of LA function in HFpEF is not known. METHODS AND RESULTS: We assessed LA function measured by speckle-tracking echocardiography in 357 patients with HFpEF enrolled in the Treatment Of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial who were in sinus rhythm at the time of echocardiography. Lower peak LA strain, indicating LA dysfunction, was associated with older age, higher prevalence of atrial fibrillation and left ventricular (LV) hypertrophy, worse LV and right ventricular systolic function, and worse LV diastolic function. At a mean follow-up of 31 months (interquartile range, 18-43months), 91 patients (25.5%) experienced the primary composite end point of cardiovascular death, HF hospitalization, and aborted sudden death. Lower peak LA strain was associated with a higher risk of the composite end point (hazard ratio, 0.96 per unit of reduction in strain; 95% confidence interval, 0.94-0.99; P=0.009) and of HF hospitalization alone (hazard ratio, 0.95 per unit of reduction in strain; 95% confidence interval, 0.92-0.98; P=0.003). The association of LA strain with incident HF hospitalization remained significant after adjustment for clinical confounders, but not after further adjustment for LV global longitudinal strain and the E/E' ratio, parameters of LV systolic and diastolic function, respectively. CONCLUSIONS: LA dysfunction in HFpEF is associated with a higher risk of HF hospitalization independent of potential clinical confounders, but not independent of LV strain and filling pressure. Impairment in LV systolic and diastolic function largely explains the association between impaired LA function and higher risk of HF hospitalization in HFpEF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.
Authors: Michael R Zile; John S Gottdiener; Scott J Hetzel; John J McMurray; Michel Komajda; Robert McKelvie; Catalin F Baicu; Barry M Massie; Peter E Carson Journal: Circulation Date: 2011-11-07 Impact factor: 29.690
Authors: M Louisa Antoni; Ellen A ten Brinke; Jael Z Atary; Nina Ajmone Marsan; Eduard R Holman; Martin J Schalij; Jeroen J Bax; Victoria Delgado Journal: Heart Date: 2011-05-25 Impact factor: 5.994
Authors: R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: Christine C Welles; Ivy A Ku; Damon M Kwan; Mary A Whooley; Nelson B Schiller; Mintu P Turakhia Journal: J Am Coll Cardiol Date: 2012-02-14 Impact factor: 24.094
Authors: Suman S Kuppahally; Nazem Akoum; Nathan S Burgon; Troy J Badger; Eugene G Kholmovski; Sathya Vijayakumar; Swati N Rao; Joshua Blauer; Eric N Fish; Edward V R Dibella; Rob S Macleod; Christopher McGann; Sheldon E Litwin; Nassir F Marrouche Journal: Circ Cardiovasc Imaging Date: 2010-02-04 Impact factor: 7.792
Authors: Amil M Shah; Sanjiv J Shah; Inder S Anand; Nancy K Sweitzer; Eileen O'Meara; John F Heitner; George Sopko; Guichu Li; Susan F Assmann; Sonja M McKinlay; Bertram Pitt; Marc A Pfeffer; Scott D Solomon Journal: Circ Heart Fail Date: 2013-11-18 Impact factor: 8.790
Authors: Eusebio García-Izquierdo; Vanessa Moñivas-Palomero; Alberto Forteza; Carlos Martín-López; Mario Torres-Sanabria; Xabier Cia-Mendioroz; Consuelo Olivo-Rodríguez; Sara Navarro-Rico; Andrés Sánchez-Gómez; Jesús G Mirelis; Miguel A Cavero; Susana Mingo-Santos Journal: Int J Cardiovasc Imaging Date: 2021-04-19 Impact factor: 2.357